Skip to main navigation Skip to search Skip to main content

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

  • Vlado Perkovic
  • , Meg J. Jardine
  • , Bruce Neal
  • , Severine Bompoint
  • , Hiddo J.l. Heerspink
  • , David M. Charytan
  • , Robert Edwards
  • , Rajiv Agarwal
  • , George Bakris
  • , Scott Bull
  • , Christopher P. Cannon
  • , George Capuano
  • , Pei-ling Chu
  • , Dick De Zeeuw
  • , Tom Greene
  • , Adeera Levin
  • , Carol Pollock
  • , David C. Wheeler
  • , Yshai Yavin
  • , Hong Zhang
  • Bernard Zinman, Gary Meininger, Barry M. Brenner, Kenneth W. Mahaffey, Srikanth Bellary
  • From the George Institute for Global Health, University of New South Wales Sydney (V.P., M.J.J., B.N., S. Bompoint), the Royal North Shore Hospital (V.P.), Concord Repatriation General Hospital (M.J.J.), and the Charles Perkins Centre, University of Sydney (B.N.), Sydney, and the Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Royal North Shore Hospital, St. Leonards, NSW (C.P.) - all in Australia; Imperial College London (B.N.) and the Department of Renal Medicine, UCL M

Research output: Contribution to journalArticlepeer-review

5131   Link opens in a new tab Citations (SciVal)
68 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science